Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Human Hepatocyte Growth Factor Naked Plasmid Injection in Critical Limb Ischemia
CTR20130671Phase 2Completed
- Sponsor
- Northland Biotech
- Start
- Dec 2016
- Modality
- Gene Therapies, Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Engensis in chronic limb-threatening ischemia (CLTI), arteriosclerosis obliterans, sponsored by Northland Biotech. Started Dec 2016; status: completed.
02
Drugs
Engensis
03
Conditions
chronic limb-threatening ischemia (CLTI)arteriosclerosis obliterans
Beyond the preview
Go deeper on CTR20130671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130671.